A Non-interventional Observational Study of Effectiveness and Safety of Nivolumab Plus Chemotherapy for Untreated Advanced / Recurrent Gastric Cancer
Latest Information Update: 10 Jan 2025
At a glance
- Drugs Nivolumab (Primary)
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms G-KNIGHT
- Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
- 12 Apr 2022 Status changed from not yet recruiting to active, no longer recruiting.
- 10 Feb 2022 New trial record